drugset / Trial / NCT01136941

Trial of Zileuton CR in Children and Adults With Sickle Cell Disease

NCT01136941

Phase 1 Completed 9 enrolled Children's Hospital Medical Center, Cincinnati
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to test the safety of Zileuton and see what effects (good and bad) it has on you, other children and adults with Sickle Cell Disease (SCD). The investigators also want to see how Zileuton is handled by your body at different doses. Zileuton is a drug that is approved by the Food and Drug Administration (FDA) for the treatment of asthma for people age 12 and older. The FDA has not approved Zileuton for the treatment of SCD, so it is being studied as an investigational drug for SCD through an application to the FDA. In asthma patients, Zileuton helps by reducing inflammation. This study will see if Zileuton helps to reduce inflammation associated with SCD.

Timeline

Start
2010-09
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Zileuton Small molecule 2.4 g Oral
Subject Zileuton Small molecule 3 g Oral

Indications